Form 4: Upstream Bio Director Receives Stock Option Grant

Director Daniella Beckman was granted 17,096 stock options in Upstream Bio, Inc. as part of standard equity compensation.

Summary

• Director Daniella Beckman received a grant of 17,096 stock options on June 9, 2026.
• The options have an exercise price of $6.69 per share.
• The options are set to expire on June 8, 2036.
• Vesting is scheduled for the earlier of June 9, 2027, or the date of the next Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $6.69 exercise price.

Future Outlook

The options vest in one year, aligning the director's tenure with the company's upcoming annual meeting cycle.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 9, 2027, or the next Annual Meeting of Stockholders.

Key Dates

Keywords

Upstream Bio, UPB, Form 4, Insider Trading, Stock Options, Director Compensation